Genitourinary Cancer

PV QA 1 - Poster Viewing Q&A 1

SU_34_2347 - Dosimetric Implication on the Simultaneous Use of Hydrogel Spacer and Endorectal Balloon for Prostate Irradiation in Proton Therapy: A Single Institution Retrospective Review

Sunday, October 21
1:15 PM - 2:45 PM
Location: Innovation Hub, Exhibit Hall 3

Dosimetric Implication on the Simultaneous Use of Hydrogel Spacer and Endorectal Balloon for Prostate Irradiation in Proton Therapy: A Single Institution Retrospective Review
Z. Xu1, T. K. Podder1,2, B. J. Traughber Jr1,2, E. T. Fredman1,2, P. Lee2,3, S. Kim2,3, C. W. Cheng1,2, F. Jesseph1, M. Machtay1,2, and R. J. Ellis III1,2; 1Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, 2School of Medicine, Case Western Reserve University, Cleveland, OH, 3Urology, University Hospitals Cleveland Medical Center, Cleveland, OH

Purpose/Objective(s): Normal tissue toxicity, especially rectal toxicity, is the limiting factor for prostate dose escalation. Several studies reported the effectiveness of rectal dose sparing by using hydrogel spacer during conformal prostate radiation therapy. This study evaluated the dosimetric benefits of using both hydrogel spacer and endorectal balloon (ERB) for patients with escalated prostate dose during image-guided proton therapy.

Materials/Methods: Twenty-nine patients with prostate cancer (stage: T1c-T2c N0M0; Gleason score ≤8; PSA≤20ng/ml) treated with parallel opposed passive scattering proton beams at our institution were retrospectively reviewed. Eleven patients received hypofractionated 70 GyRBE in 28 fractions and eighteen patients received conventional fractionated 79.2 GyRBE in 44 fractions, with intermediate-risk patients receiving 45 GyRBE to the prostate and proximal seminal vesicles and 34.2 GyRBE to the prostate only. PTV was derived from CTV with 5 mm uniform margin. A hydrogel spacer was injected in the recto-prostatic space. The ERB with 50 cc filling prevented prostate mobilization and allowed rectal gas to pass through the balloon’s internal lumen during setup and delivery of daily treatment while allowing reduced beam aperture margins. Dosimetric evaluation was performed for bladder, rectum, CTV and PTV in the treatment planning system.

Results: Mean V100 for CTV and PTV were 100% and 97.0%±1.8%, respectively. Compared with RTOG constraints, reduction in bladder V65&V64 was 75.8% while reduction in rectum V65&V64, V70&V69, and V75&V74 were 82.6%, 85.2%, and 88.0%, respectively (Table 1).

Conclusion: To our knowledge, this is the first ever report on the simultaneous use of both ERB and hydrogel spacer in prostate irradiation with passive scattering proton beams. Using ERB and hydrogel spacer for patients treated with escalated prostate dose can substantially reduce rectum and bladder doses while maintaining sufficient target coverage. Either ERB or hydrogel spacer serves a different purpose and is applied independently in prostate cancer treatment using IMRT and proton therapy. The hydrogel spacer provides extended separation between the prostate and the anterior rectal wall and has level 1 evidence showing a reduction in rectal dose and treatment related toxicity in IMRT. Further studies are warranted to evaluate both acute and late toxicities in this clinical scenario.
Table 1 Dosimetric parameters and RTOG constraints for bladder and rectum
Parameters Mean±SD RTOG Constraints Reduction
Rectum V40 18.5%±8.9% 55%a -66.3%
Rectum V50 12.5%±7.3% 50%b -75.0%
Rectum V65+&V64* 6.1%±4.7% 35%c -82.6%
Rectum V70+&V69* 3.7%±3.8% 25%c -85.2%
Rectum V75+&V74* 1.8%±2.8% 15%c -88.0%
Bladder V40 22.6%±15.1% 70%a -67.7%
Bladder V65+&V64* 12.1%±9.6% 50%c -75.8%
+: dose constraints for 1.8Gy/fx regimen; *: dose constraints for 2.5Gy/fx regimen; a: RTOG 0534; b: RTOG 0621; c: RTOG 0415

Author Disclosure: Z. Xu: None. T.K. Podder: None. B.J. Traughber: Employee; Philips Healthcare. E.T. Fredman: None. P. Lee: None. C. Cheng: collaborator; PerkinElmer. F. Jesseph: None. M. Machtay: Research Grant; Abbvie. Consultant; Stemnion Inc, Abbvie. Advisory Board; Stemnion Inc. Deputy Chair; RTOG Foundation, NRG Oncology Group. R.J. Ellis: Partner; ADvanced Clinical Solutions Inc. Honoraria; Augmentix. Consultant; Radiadyne. Patent/License Fees/Copyright; ADvanced Clinical Solutions.

Send Email for Zhengzheng Xu


Assets

SU_34_2347 - Dosimetric Implication on the Simultaneous Use of Hydrogel Spacer and Endorectal Balloon for Prostate Irradiation in Proton Therapy: A Single Institution Retrospective Review



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Dosimetric Implication on the Simultaneous Use of Hydrogel Spacer and Endorectal Balloon for Prostate Irradiation in Proton Therapy: A Single Institution Retrospective Review